• Impact Therapeutics’ board resolved to repurchase up to HK$ 100 million of H Shares on the open market, including transaction costs.
• Repurchases will use internal financial resources, excluding global offering proceeds, under the mandate granted June 25, 2026.
• Repurchased H Shares may be canceled or held in treasury at the board’s discretion.
• No H Shares had been repurchased under the mandate as of November 4, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Therapeutics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261104-12398424), on November 03, 2026, and is solely responsible for the information contained therein.